{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Participants": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Intervention": {
        "score": 2,
        "evidence": "The 3-mo 2-h OGTT (end of treatment) was 141.00 \u00b1 62.44 mg/dL in the sitagliptin arm and 165.22 \u00b1 72.03 mg/dL ( P = 0.218) in the placebo arm."
      },
      "Objective": {
        "score": 1,
        "evidence": "The primary efficacy objective was to improve 2-h oral glucose tolerance test (OGTT) by > 20 mg/dL at 3 mo posttransplant."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary efficacy objective was to improve 2-h oral glucose tolerance test (OGTT) by > 20 mg/dL at 3 mo posttransplant."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Sixty-one patients consented, and 50 patients were analyzed."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Sixty-one patients consented, and 50 patients were analyzed."
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The 3-mo 2-h OGTT (end of treatment) was 141.00 \u00b1 62.44 mg/dL in the sitagliptin arm and 165.22 \u00b1 72.03 mg/dL ( P = 0.218) in the placebo arm."
      },
      "Harms": {
        "score": 1,
        "evidence": "Participants tolerated sitagliptin well."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 10,
    "max_score": 25
  },
  "model": "gpt-4o"
}